As communicated on
PrimECC is a solution used to prime the heart-lung machine before heart-surgery. It is a CE-marked and patent-protected product and is developed to reduce postoperative complications. In 2020 a study was initiated to expand and strengthen the clinical data for PrimECC. As communicated, the pace of patient recruitment to this study has not met expectations and as recruitment was not projected to be finalized within a reasonable period of time the study was closed.
XVIVO’s assessment of opportunities for the product has resulted in a decision to write down the asset in accordance with IFRS accounting standards. The write-down in the fourth quarter amounts to
“With the decision to write-down PrimECC, we will instead increase our focus on our core business within organ transplantation. There, significant opportunities deserve our full attention to fulfill our vision that 'nobody should die waiting for a new organ’”, says
© Modular Finance, source